Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05724173 · ClinicalTrials.gov registry record · NA

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia

A NA study of Spinal Cord Injuries and Amyotrophic Lateral Sclerosis, sponsored by Leigh R. Hochberg, MD, PhD..

Recruiting
Registry status
NA
Development phase
3
Enrollment target
2
Study locations

NCT05724173 is a NA study of Spinal Cord Injuries and Amyotrophic Lateral Sclerosis that is actively recruiting participants, run by Leigh R. Hochberg, MD, PhD.. The registered enrollment target is 3 participants, below the 62-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05724173, a NA study of Spinal Cord Injuries and Amyotrophic Lateral Sclerosis, is actively recruiting participants, sponsored by Leigh R. Hochberg, MD, PhD..

RECRUITING
Registry status
NA
Development phase
3 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.

Interventions

  • DEVICE BrainGate Neural Interface System

Study Locations (2)

California

  • Stanford University School of Medicine - Stanford

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2023-10-18
Est. Completion 2026-12
Phase NA

Sponsor

Leigh R. Hochberg, MD, PhD.

4 total trials

What the Registry Record Tells You About NCT05724173

The ClinicalTrials.gov registry entry for NCT05724173 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (95% lower). The listed sponsor is Leigh R. Hochberg, MD, PhD., which has 4 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Spinal Cord Injuries appearing as the primary indexed condition, and to 1 intervention - of which BrainGate Neural Interface System is the first listed.

NCT05724173 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05724173 about?

NCT05724173 is a clinical study titled "Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia". The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.

What is the current status of trial NCT05724173?

This trial is currently recruiting. It is a NA study. The enrollment target is 3 participants. The study started on 2023-10-18. Estimated completion is 2026-12.

What conditions does trial NCT05724173 study?

This clinical trial studies the following conditions: Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Tetraplegia, Muscular Dystrophies, Dysarthria.

What interventions are being tested in trial NCT05724173?

The interventions under investigation include: BrainGate Neural Interface System (DEVICE).

Who is sponsoring clinical trial NCT05724173?

This trial is sponsored by Leigh R. Hochberg, MD, PhD., which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05724173 being conducted?

This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spinal Cord Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.